Literature DB >> 9774169

Beta-amyloid (1-42) peptide impairs blood-brain barrier function after intracarotid infusion in rats.

G Jancsó1, F Domoki, P Sántha, J Varga, J Fischer, K Orosz, B Penke, A Becskei, M Dux, L Tóth.   

Abstract

The effects of intracarotid infusions of beta-amyloid (1-42) peptide was studied on the permeability of brain vessels. Using a quantitative Evans blue method a dose-dependent increase of brain tissue albumin content was established following intracarotid injections of the peptide. Cerebral vessels of increased permeability were also demonstrated with a vital 'staining' technique. Lectin histochemistry revealed an almost complete abolition of specific lectin binding sites of affected endothelial cells. The findings indicate a significant deterioration by beta-amyloid (1-42) peptide of blood-brain barrier function and suggest that this may result from endothelial damage. It is assumed that altered permeability of cerebral vessels may be involved in the development of brain pathologies associated with Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774169     DOI: 10.1016/s0304-3940(98)00622-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  17 in total

Review 1.  Strategies to improve drug delivery across the blood-brain barrier.

Authors:  Albertus G de Boer; Pieter J Gaillard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Alzheimer's disease drug development and the problem of the blood-brain barrier.

Authors:  William M Pardridge
Journal:  Alzheimers Dement       Date:  2009-09       Impact factor: 21.566

3.  Delivery of Polymeric Nanoparticles to Target Vascular Diseases.

Authors:  Edward Agyare; Karunyna Kandimalla
Journal:  J Biomol Res Ther       Date:  2014-01

Review 4.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

Review 5.  Alzheimer's disease, brain immune privilege and memory: a hypothesis.

Authors:  Y I Arshavsky
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

Review 6.  Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.

Authors:  William A Banks
Journal:  Adv Drug Deliv Rev       Date:  2011-12-17       Impact factor: 15.470

7.  Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain.

Authors:  Qing-Hui Zhou; Ailing Fu; Ruben J Boado; Eric Ka-Wai Hui; Jeff Zhiqiang Lu; William M Pardridge
Journal:  Mol Pharm       Date:  2010-12-21       Impact factor: 4.939

Review 8.  Brain endothelial cells as pharmacological targets in brain tumors.

Authors:  Michel Demeule; Anthony Régina; Borhane Annabi; Yanick Bertrand; Michel W Bojanowski; Richard Béliveau
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

9.  Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers.

Authors:  Francisco J Gonzalez-Velasquez; Joseph A Kotarek; Melissa A Moss
Journal:  J Neurochem       Date:  2008-09-16       Impact factor: 5.372

10.  IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey.

Authors:  Ruben J Boado; Jeff Zhiqiang Lu; Eric Ka-Wai Hui; William M Pardridge
Journal:  Biotechnol Bioeng       Date:  2010-02-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.